Rheumatology: biologic authorizations, buy-and-bill economics, and injections
Rheumatology practices carry real financial risk because they purchase expensive biologics and infuse them before payment. Authorization, step therapy, and site-of-care policies all have to be settled before a drug is ordered, since a denial after infusion is not an accounts receivable problem but an inventory loss. Some plans mandate specialty pharmacy or an alternative site, which changes the economics entirely, and reauthorization dates need to be managed as a calendar so therapy is not interrupted or delivered outside an approval.
Claim accuracy then protects the margin. Drug units must be converted correctly from the dose, waste from single-dose vials reported with the appropriate modifier, and infusion services reported under the hierarchy with documented start and stop times. Joint injections are reported by joint size and laterality, and ultrasound guidance is separately billable only with a retained image and interpretation. Bone density and laboratory monitoring carry frequency rules. We secure authorizations before ordering and audit drug units, waste, and infusion times on every claim.
Coding and documentation focus
- ✓Authorization and step therapy sequencing — Approval, step therapy history, and site-of-care requirements must be resolved before the drug is purchased.
- ✓Drug units and waste reporting — Units are converted from the administered dose, with discarded amounts from single-dose vials reported by modifier.
- ✓Infusion hierarchy and timing — One initial service per encounter with add-ons for sequential and additional hours, each supported by documented times.
- ✓Injections with imaging guidance — Joint injections are reported by joint size and side, and guidance requires a retained image and interpretation.
Denials we prevent on these claims
- ✓Biologic infused before authorization was confirmed — prevented by ordering only against an active approval.
- ✓Plan required specialty pharmacy rather than buy-and-bill — identified during benefit verification.
- ✓Drug units or waste misreported — reconciled to dose and vial on every claim.
- ✓Guidance billed without a retained image — flagged back to the provider.
Frequently asked questions
How do we avoid losing money on biologic infusions?
By confirming an active authorization, the step therapy history, and the plan site-of-care requirement before the drug is ordered, and by tracking reauthorization dates ahead of expiry. Under buy-and-bill the practice owns the inventory, so a post-infusion denial is a direct loss rather than a collectible balance.
How should infusion time be documented?
With actual start and stop times for each infusion, because the hierarchy pays one initial service per encounter and everything else as sequential or additional-hour add-ons. Without discrete times, additional hours and sequential services cannot be supported and are removed on review.